RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboONCY's synergy with bispecifics is even better than with anti-body drug conjugates (ADC) since ADCs are usually loaded with a chemotherapy agent while bispecifics are antibodies with two binding sites directed at two different antigens such as pelareorep + a CD3 surface antigen - which results in a more specific,, more effective and less toxic I/O agent than that of an ADC.
More importantly for ONCY, both Roche and Pfizer are bispecitic players.